Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team

Autor:	P, Mylona, J G, Cleland
Rok vydání:	2000
Předmět:	Adult Aged 80 and over Heart Failure Male Sulfonamides Endothelins Adrenergic beta-Antagonists Bosentan Middle Aged United States Ventricular Function Left Europe Survival Rate Double-Blind Method Humans Female Antihypertensive Agents Aged Metoprolol
Zdroj:	European journal of heart failure. 1(2)
ISSN:	1388-9842
Popis:	This article reviews the design and results of REACH-1 (Research on Endothelin Antagonism in Chronic Heart Failure) and MERIT (Metoprolol controlled and Extended release, Randomised Intervention Trial in congestive Heart Failure), two recently reported clinical trials that investigated, respectively, the role of a non-selective endothelin antagonist (bosentan) and of a beta-selective blocker for the treatment of heart failure.The REACH-1 trial demonstrated that initiation of bosentan therapy is associated with an increased risk of worsening heart failure. However, long-term therapy with bosentan may have improved symptoms and favourably altered the progression of heart failure. The MERIT-HF clinical trial indicated that beta-blockade using metoprolol confers a significant beneficial effect on total mortality in patients with stable chronic heart failure.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::d377f20dc6871cb54aeea46257437fa5 https://pubmed.ncbi.nlm.nih.gov/10937931 Zobrazit plný text záznamu Plný text